Linear growth was recorded in 36 children with juvenile chronic arthritis. In 20, the hypothalamic-pituitary-adrenal axis (HPA axis) was assess~d by insulininduced hypoglycaemia, the results of which correlated well with resting cortisol levels. Three groups were identified according to type of corticosteroid regimen administered. Group I (6 children), receiving daily corticosteroid therapy, were clearly suppressed and failing to grow. Group 2 (13 children) had received an alternate-day regimen from the initiation of corticosteroid therapy; they were not suppressed and growth was satisfactory in II. Group 3 (17 children) were receiving alternate-day therapy, but had had daily corticosteroid in the past; they showed no clear pattern of suppression or growth. Factors influencing the recovery of the HPA axis and resumption of growth were assessed. No difference was found in the individual growth of 7 children who commenced alternateday therapy before the age of 5, compared with matched controls.
Introduction
Corticosteroid therapy may still sometimes be required in the management of juvenile chronic arthritis (lCA), especially to control serious systemic features, or as an adjunct to management in arthritis which is failing to respond to a full conservative regime. Suppression of the hypothalamic-pituitary-adrenal axis (HPA axis) occurs with daily divided doses, and serious stunting of growth is also seen (Bacon & Spencer 1973) . In particular, very young children fail to grow on doses of corticosteroids that older children can tolerate (Blodgett et al. 1956 ). Administration of an alternate-day regimen has been advocated to avoid these side effects (Harter et al. 1963 , Soyka 1967 .
In this study, the effects of differing corticosteroid regimens on linear growth in children with leA, especially those commencing steroids before the age of 5, were investigated. The usefulness of resting cortisol levels as a guide to the function of the HPA axis was also assessed.
Methods
Linear growth was measured in 36 children with lCA (Table I) by plotting height regularly on standard percentile growth charts (Tanner et al. 1966) . For each child details of past and present corticosteroid therapy were recorded; three groups of children were identified (Table 2) . Group I were receiving daily therapy, Group 2 had received only alternate-day therapy from initiation of corticosteroid therapy, and Group 3 had taken daily corticosteroids in the past, but had since been converted to an alternate-day regimen. The prednisolone dosage varied considerably, the maximum daily dose being 0.6 mg/kg compared with I mg/kg on alternate days.
The two groups currently on an alternate-day regimen included a number of children who were receiving up to 2 mg prednisolone on the alternate day, as previous work (Ansell & Bywaters 1974) has shown that when converting from a daily to an alternate-day regimen, growth resumes and resting cortisol levels rise when the alternate-day dose reaches 2 mg. Of particular interest was a group of 7 children who commenced alternate-day therapy before the age of 5. Their growth was compared with that of controls over a one-year period. Each control was matched for age, sex, duration and pattern of disease, and had never received corticosteroids ( Figure I ). The use of standard charts for children's height, allowing for parental height (Tanner et al. 1970) , enabled assessment of whether these 14 children had attained the expected height for their age.
Height velocity (Tanner et al. 1966 ) was assessed over one whole year, and tests of HPAaxis function were carried out at the midpoint of that year. All the children were accustomed to venepuncture, but to minimize the effect of stress and exercise, resting cortisols, measured on at least two consecutive occasions, were taken between 07: 00 and 07: 30 hours with the child hardly awake. The cortisol secretion in response to hypoglycaemia (standard insulin tolerance test: ITT) was measured in 20 children as a test of HPA-axis function. The normal resting plasma cortisol was taken as 0.32-0.75 Jlmol/I and the response to hypoglycaemia was considered normal if the peak cortisol exceeded 0.55 Jlmol/l. Blood sugar determinations were carried out using a glucose oxidose method (Trinder 1969) , and plasma cortisol by the method of Mattingly et al. (1964) with additional alkali wash.
Results
Nineteen of the 20 children who underwent an ITT reached a satisfactory level of hypoglycaemia; 12 were found to be suppressed, and 7 non-suppressed. A positive correlation was found between the average resting cortisol for each child and the peak cortisol recorded during hypoglycaemia, the correlation coefficient (r value) being 0.73. The Figure 2) . This difference is statistically significant (P =0.002, using two-tailed Student's t test, with Bessel's correction). Accepting a lower limit of resting cortisol of 0.32 Jlmol/I, 75% of suppressed children and 86% of non-suppressed children are correctly identified. Thus true resting cortisol levels are useful in assessing HPA-axis function.
As would be expected in a group of children receiving corticosteroid therapy (Table I) , there was a preponderance of systemic disease with a high proportion of males, reflecting both the frequency and severity of systemic disease in this sex. The children in Group 2 (Table 2) tended to be younger, with a shorter duration of disease and duration of corticosteroid therapy than children in the other two groups. This is partly explained by the slight preponderance of pauci-articular disease in this group, but also probably reflects the changing pattern of corticosteroid prescribing.
When comparing the height velocities of the three groups of children, distinct differences were seen ( Figure 3A ). Children receiving daily corticosteroids were clearly not growing, all their height velocities being below the third percentile. Eleven of the 13 children who had only ever received alternate-day therapy were growing satisfactorily. The children who had received daily therapy in the past showed no clear pattern, as some had recovered from the effect of daily therapy and others had not.
The pattern of resting cortisol levels in the three groups of children tended to parallel that for height velocity ( Figure 3B ): children in Group 1 had clearly suppressed levels; those in Group 2 had normal levels; and those in Group 3 showed various stages of recovery of the HPA axis. Growth appeared to resume before recovery of the HPA axis was complete. The height velocities of the children who underwent an ITT were compared ( Figure 4) ; 4 of the 12 suppressed children were growing. All these children were from Group 3, and were recovering from daily therapy. Therefore, growth resumption alone is not a reliable indication of HPA-axis recovery. Factors determining the speed of recovery of the HPA axis were assessed. It appeared that once suppression had occurred, recovery was not seen until the child had been on alternateday therapy, with a maximum of 2 mg on the 'off' day, for at least 12 months, and that the period of alternate-day therapy had to equal the duration of daily therapy before recovery of the HPA-axis could be expected. Several results also illustrated that during the recovery phase there is a period when resting cortisol levels are normal, but response to hypoglycaemia is diminished. Thus resting cortisol results must be interpreted with care for each individual in the light of his previous corticosteroid therapy. Two consecutive resting cortisol estimations are recommended, as the result 22 hours after a dose of prednisolone is usually considerably lower than the result 46 hours afterwards.
The growth results comparing controls with the 7 children who commenced alternate-day therapy before the age of 5 are shown in Figure I . Although there is a trend suggesting that the steroid-treated children were growing at a faster rate than their controls, using a paired t test no significant difference could be found between the groups. When potential height was taken into consideration, all of the control children, but only 5 of the steroid-treated children, had attained the expected height for their age. Both disease activity and corticosteroid therapy might have played a part in the 2 children who were stunted in growth. However, both of these children had height velocities on the 50th percentile at the time of the study, suggesting that they were currently in the process of 'catching up' in growth, possibly because their disease activity was better controlled. 
Discussion
The factors which control growth are complex, and any chronic disease -in particular juvenile chronic arthritis -may impair growth, which is then further aggravated by corticosteroid administration. It is impossible completely to separate the effects of these two factors. In our study population, the majority of children had suffered prolonged active disease, yet most of those on alternate-day therapy were growing satisfactorily ( Figure 3A) , and all the children on daily therapy were not growing, including one boy who received daily corticosteroids for iridocyclitis and not because of active arthritis. It is tempting to suggest that judicious corticosteroid therapy may allow more normal growth by controlling disease activity, and certainly observations on our young children would support this (Figure 1) , though greater numbers of children would have to be followed over a period of time to demonstrate it. There is debate as to whether or not alternate-day corticosteroids can induce remission in an inflammatory disease (Fauci 1978 , Garber et al. 1981 , Axelrod 1976 , though in certain clinical conditions, e.g. asthma and nephrotic syndrome, control of disease has been attained with such a regimen (Kuzemko & Lines 1971 , Soyka 1967 , MacGregor et al. 1969 . In juvenile arthritis the aim of therapy is to suppress the disease process sufficiently that fever is reduced, general well-being is improved, and joint position and function maintained, as ultimately this is a self-limiting disease although there may be a very prolonged period of activity.
Although dose and duration of corticosteroid therapy are important (Blodgett et al. 1956) , the regimen of administration seems to playa bigger part in terms of effect on growth. In our study, children were failing to grow on daily dosages as low as 0.4 mg/kg/24 hours, but could tolerate alternate-day dosages of 1 mg/kg/48 hours. Timing of dosage appears to be equally important: we have seen children on alternate-day regimens, but taking their steroid in the evening or in divided doses on the alternate day, who have been suppressed and failing to grow.
The effect of corticosteroids on growth is believed to be primarily due to peripheral antagonism of the action of growth hormone (Loeb 1976) , possibly via somatomedin mediators (Elders et al. 1975) . Corticosteroids also have the capacity to inhibit pituitary secretion of growth hormone (GH), but treatment with large doses of GH has not been successful in overcoming growth retardation in steroid-treated children (Morris et al. 1968 , Ward et al. 1966 . At this unit, Sturge et al. (1970) showed that growth retardation in patients with lCA receiving corticosteroids was not due to an inability to secrete GH; the children in that study showed a normal GH response to hypoglycaemia. This was confirmed in the first few children we tested, and it was considered unnecessary to subject any further patients to this test.
No formal assessment of corticosteroid side effects was undertaken in this study, but to date none of the children who commenced steroid therapy with an alternate-day regimen has developed any problems. All of the children who had received daily therapy had suffered at least one side effect, the commonest being collapsed vertebrae (Elsasser et al. 1982) . It is appreciated that complications can occur in alternate-day therapy, but they are much less frequent (Ansell & Bywaters 1974) .
Our data would suggest that in severe juvenile chronic arthritis, the judicious use of corticosteroids in an alternate-day regimen may allow growth to continue, whilst having minimal effect on hypothalamic-pituitary-adrenal function, even in young children.
